Post-Surgery Recovery
88
síntesis
3
7,000
intermediate
May 17, 2026
Visión General
The Post-Surgery Recovery stack is designed for accelerated healing following surgical procedures, combining tissue-repair peptides with immune support to address the dual challenges of wound healing and infection prevention. BPC-157 at standard dosing promotes angiogenesis and growth factor expression at surgical sites, while TB-500 is used at a higher loading dose (5000mcg) to maximize its systemic anti-inflammatory and tissue-migration effects during the critical early post-operative window. Thymosin Alpha-1 (Ta1) is the immune-support cornerstone of this stack. It is a 28-amino-acid peptide originally isolated from thymic tissue that enhances T-cell maturation, dendritic cell activation, and natural killer cell function. Ta1 is approved in over 35 countries under the brand name Zadaxin for hepatitis B/C and as an immune adjuvant. In the post-surgical context, it helps prevent opportunistic infections during the immunosuppressive period following anesthesia and surgical trauma, while also modulating inflammation to prevent excessive scarring. The synergy here is particularly elegant: BPC-157 and TB-500 handle the structural repair — new blood vessel formation, cellular migration, extracellular matrix deposition, and anti-inflammatory signaling — while Thymosin Alpha-1 ensures the immune system remains vigilant against post-surgical infections without triggering excessive inflammatory responses that could impair healing. This combination addresses the clinical reality that surgical recovery requires both tissue repair and immune competence, and that these processes must be balanced rather than maximized independently. This stack should only be used under physician supervision, ideally beginning 24-48 hours after surgery once initial hemostasis is established.
Protocolo de Dosis
250 mcg
por dosis
5,000 mcg
por dosis
1,500 mcg
por dosis
Objetivos & Evidencia
Advertencias
- Must be supervised by prescribing physician. BPC-157 and TB-500 were removed from FDA Category 2 (April 2026) but remain pending PCAC review — not legal to compound yet. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad in 35+ countries as Zadaxin).
Comments
Sign in to join the discussion
Aviso: Este stack es subido por la comunidad y solo tiene fines de investigación. Peptide Contacts no verifica la seguridad o eficacia de los stacks subidos. Siempre consulte a un profesional de la salud calificado antes de usar cualquier protocolo de péptidos.